Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Evolus Inc (EOLS)

Evolus Inc (EOLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 451,565
  • Shares Outstanding, K 56,095
  • Annual Sales, $ 99,670 K
  • Annual Income, $ -46,810 K
  • 60-Month Beta 2.01
  • Price/Sales 4.37
  • Price/Cash Flow N/A
  • Price/Book 9.29
Trade EOLS with:

Options Overview Details

View History
  • Implied Volatility 74.88% ( -22.15%)
  • Historical Volatility 64.72%
  • IV Percentile 15%
  • IV Rank 16.28%
  • IV High 125.80% on 05/06/22
  • IV Low 64.98% on 09/15/22
  • Put/Call Vol Ratio 11.33
  • Today's Volume 111
  • Volume Avg (30-Day) 166
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 5,893
  • Open Int (30-Day) 6,208

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.35
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.59 +6.06%
on 09/29/22
11.00 -26.82%
on 09/12/22
-2.20 (-21.46%)
since 08/30/22
3-Month
7.59 +6.06%
on 09/29/22
14.29 -43.67%
on 07/20/22
-3.55 (-30.60%)
since 06/30/22
52-Week
5.06 +59.06%
on 01/24/22
14.34 -43.86%
on 05/17/22
+0.43 (+5.64%)
since 09/30/21

Most Recent Stories

More News
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, this month celebrated the conclusion of certain royalty payments...

EOLS : 8.05 (+3.74%)
Evolus Announces Inducement Grants for New Chief Financial Officer

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Compensation Committee of the Board of Directors...

EOLS : 8.05 (+3.74%)
Evolus Appoints Sandra Beaver as Chief Financial Officer

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has named Sandra Beaver as its Chief Financial Officer, effective...

EOLS : 8.05 (+3.74%)
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating...

EOLS : 8.05 (+3.74%)
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that a peer-reviewed, post hoc analysis published...

EOLS : 8.05 (+3.74%)
Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?

These beaten-down stocks share a favorable outlook for their aesthetic segments.

AGN.AX : 0.450 (-6.25%)
ABBV : 134.21 (-5.96%)
INMD : 29.11 (+1.50%)
EOLS : 8.05 (+3.74%)
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EOLS : 8.05 (+3.74%)
CGC : 2.73 (-1.80%)
Evolus Reports Second Quarter 2022 Results and Provides Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the second quarter ended June...

EOLS : 8.05 (+3.74%)
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

DCPH : 18.50 (+4.99%)
EOLS : 8.05 (+3.74%)
Evolus to Report Second Quarter 2022 Results and Provide Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its second quarter 2022 financial...

EOLS : 8.05 (+3.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

3rd Resistance Point 8.79
2nd Resistance Point 8.48
1st Resistance Point 8.27
Last Price 8.05
1st Support Level 7.75
2nd Support Level 7.44
3rd Support Level 7.23

See More

52-Week High 14.34
Fibonacci 61.8% 10.80
Fibonacci 50% 9.70
Fibonacci 38.2% 8.61
Last Price 8.05
52-Week Low 5.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar